171 Diagnostic utility of molecular and imaging biomarkers 2 Table 33. Baseline characteristics of included studies investigating the Afirma® GEC malignant histology, ni reference country study design ntot ni included indeterminate cytology other inclusion and exclusion criteria malignant PTC FVPTC FTC FTC-OV MTC mPTC other n.s. Alexander 2012 USA PS 265 210 Bethesda III or IV US-confirmed TN ≥1cm; adequate RNA sample; timely shipping of sample 32% 51 Alexander 2014 USA RS 339 326 Bethesda III or IV US-confirmed TN ≥1cm; US-FNAC performed 16% 40 5 1 1 1 Harrell 2014 USA n.s. 645 58 Bethesda III or IV TN; US-FNAC 33% 13 3 1 1 1 Lastra 2014 USA RS 132 132 Bethesda III or IV TN; US-FNAC; archived cytology; Afirma GEC performed 46% 2 17 3 McIver 2014 USA PS 105 72 Bethesda III or IV patient age >21y; TN >1.0cm; US-FNAC; decision for thyroid surgery not based on worrisome clinical features 10% 1 1 2 1 1 Sullivan 2014 USA RS 332 14 Bethesda III TN; Afirma GEC performed; no history of thyroid cancer; decision for thyroid surgery not based on other reasons 15% 2 Brauner 2015 USA RS 134 72 Bethesda III or IV, and SHCN patient age ≥21y; TN; Afirma GEC performed; decision for thyroid surgery not based on worrisome clinical features 8% 2 4 Celik 2015 USA RS 66 40 Bethesda III or IV TN 50% 9 1 Marti 2015 USA RS 165 165 Bethesda III or IV TN; no incidental carcinoma elsewhere in thyroid 16% 7 16 2 1 1 Noureldine 2015 USA RS 273 222 Bethesda III or IV TN; Afirma GEC performed; histological f/u available; no positive test for MTC or non-follicular tumor cells 35% 77 Witt 2016 USA RS 32 32 Bethesda III or IV TN; clinically nonsuspicious; US-FNAC; clinical or histological f/u available; no (family) history for thyroid cancer or neck irradiation 21% 6 Wu 2016 USA PS 214 214 Bethesda III or IV TN; routine Afirma GEC performed, clinical or histological f/u available 24% 52 Yang 2016 USA RS 217 189 Bethesda III or IV TN; no incidental carcinoma elsewhere in thyroid 17% 12 18 2 TOTAL 2,919 1,746 20.3% 86 57 11 11 2 3 2 186 FTC: follicular thyroid carcinoma. FTC-OV: FTC, oncocytic variant (Hürthle cell carcinoma). FVPTC: papillary thyroid carcinoma, follicular variant. mPTC: papillary thyroid microcarcinoma. MTC: medullary thyroid carcinoma. ni: total number of indeterminate thyroid nodules included in our analysis. n.s.: not specified. ntot: total number of thyroid nodules in study. PS: prospective. PTC: papillary thyroid carcinoma. RS: retrospective. SHCN: suspicious for Hürthle cell neoplasm. TN: thyroid nodule. y: years.
RkJQdWJsaXNoZXIy MTk4NDMw